Category Archives: Biotechnology

NIGERIAN TRIBUNE (press release) (blog) When OFAB gathered professionals for biotechnology NIGERIAN TRIBUNE (press release) (blog) Recently, the Open Forum of Agricultural Biotechnology (OFAB) gathered professionals to brainstorm on how best to convey the message of science to Nigerians. In Nigeria, farmers who will be the users of this technology if it is adopted in the country ... See the article here: When OFAB gathered professionals for biotechnology - NIGERIAN TRIBUNE (press release) (blog) … Continue reading →

"Forge is a very exciting, emerging life science company its novel platform and programs, its highly efficient business model, and its creative capitalization all attracted me to join the Board at such a pivotal time in the company's evolution," said John Schmid. "I look forward to providing strategic, operational and financial guidance to the management team in the coming years." Dr. Worland added, "Multi-drug resistant bacteria 'superbugs' pose a very serious threat to human health and Forge's novel antibiotic program provides a promising solution to this global problem. I am honored to join the Forge Board and excited to work with its talented management team, advisors, and alliance and government partners as the company and technology platforms mature." About the Forge Board of Directors Forge's Board of Directors is a well-balanced composition of San Diego biotechnology industry veterans, global drug development experts and corporate finance leaders. About Forge Therapeutics Forge Therapeutics is a privately-held biopharmaceutical companydeveloping novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic. With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes. Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and … Continue reading →

Biotechnology is one of the more tempting and complex areas of the broader healthcare sector investing. However, stock-picking in this space is tricky, which has made biotechnology exchange-traded funds popular with investors. The most popular as well as the largest biotechnology ETF is the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB). The $8.2 billion IBBtracks the Nasdaq Biotechnology Index. The funddebuted in 2001, and currently holds 162 stocks. While IBB has a deep bench relative to other biotechnology ETFs, investors should look under the hood to ensure this is the type of biotech fund they want to be involved with. For example, investors often hear about biotechnology stocks that deliver jaw-dropping short-term gains on the back of favorable Food & Drug Administration (FDA) news. Then there are the biotechcompanies that are able to prove durable over time, delivering stellar returns for investors for years on end. While it is hard to say biotechnology is a sector for conservative investors, given the historical volatility associated with the group, IBB can be viewed as one of the more conservative biotechnology ETFs due to its emphasis on the groups biggest names. IBB is a cap-weighted ETF and as such allocates significant percentages of its … Continue reading →

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases. Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal. Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and … Continue reading →

Shares ofCellect Biotechnology Ltd (APOPW) aremoving on volatility today-2.87% or $-0.09 from the open.TheNASDAQ listed companysaw a recent bid of3.05 and11012shares have traded hands in the session. Now letstake a look at how the fundamentals are stacking up for Cellect Biotechnology Ltd (APOPW). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Cellect Biotechnology Ltd currently has a yearly EPS of -0.14. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis. Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. Cellect Biotechnology Ltd (APOPW) currently has Return on Equity of -86.72. ROE is a ratio that measures profits generated from the investments received from shareholders. In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further … Continue reading →

Prana Biotechnology Limited (NASDAQ:PRAN) are being monitored closely by investors today as the name is currently priced at$2.22, a-1.77% difference from where it most recently opened. So where is the stock headed from here? We will take a quick look here at how the stock has performed recently. Most investors are likely looking for that next stock that is ready to take off running. Maybe the focus is on finding a stock that has recently taken a turn for the worse for no real apparent reason. As we all know, as quickly as a stock can drop in price, it can bounce back just as fast. Although the popular stocks that receive a high level of media coverage tend to recover quicker after a sell-off, there may be plenty of under the radar stocks that are ripe for buying. Scoping out these potential market gems may help repair a portfolio that has taken a hit for any number of reasons. Is Prana Biotechnology Limited Ready to Move higher? Sign Up For Breaking Alerts on this Stock Before the Crowd. The average investor might not have the time to monitor every single tick of a given stock, but taking a look … Continue reading →

A National Biosafety Authority Appeal Tribunal has been inaugurated to handle concerns of aggrieved persons on issues regarding applications and other matters under the Biosafety Act. The tribunal, which will serve as a regulatory body to guide the application and use of biotechnology in order to prevent its abuse, will also adjudicate on matters and concerns of clients. Membership The five-member Appeal Tribunal is chaired by the Pro Vice-Chancellor of the University of Ghana, Professor Samuel Kwame Ofei. The other members are the Vice Dean, Faculty of Agriculture of the University for Development Studies (UDS), Professor Albert Kojo Quainoo; a Principal State Attorney of the Ministry of Justice, Mrs Grace Ama Issahaque; a plant biotechnologist with the Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Dr Peter Twumasi, and a former Assistant Commissioner and Head of the Ghana Customs Laboratory, Mrs Dinah Brandful. Inaugurating the tribunal in Accra yesterday, the Minister of Environment, Science, Technology and Innovation, Professor Kwabena Frimpong-Boateng, said the appeal tribunal was to serve the interest of the public and that anyone who was aggrieved in the implementation of the Biosafety Act could appeal to the tribunal. For example, if somebody is refused a permit under … Continue reading →

USA Commerce Daily Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst's Predictions StockNewsJournal Investors who are keeping close eye on the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) established that the company was able to keep return on investment at -130.59 in the trailing twelve month while Reuters data showed that industry's average ... The Dirty Secret to Trading Puma Biotechnology, Inc. (PBYI), TETRA Technologies, Inc. (TTI)USA Commerce Daily A Look at the valuation of Puma Biotechnology, Inc. (NasdaqGS:PBYI)Business Review Puma Biotechnology Inc (PBYI) PT Set at $40.00 by Royal Bank of CanadaMarkets Daily Stocks Gallery -Bibeypost.com -The De Soto Edge all 8 news articles » Read more here: Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst's Predictions - StockNewsJournal … Continue reading →

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Puma did not anticipate that the U.S. Food and Drug Administration ("FDA") would ultimately approve PB272 ("neratinib") for the treatment of breast cancer; (2) consequently, Puma Biotechnology had overstated the drug's approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology's public statements were materially false and misleading at all relevant times. On May 4, 2017, post-market, Puma revealed that Dr. Robert Charnas, the Company's Senior Vice President, Regulatory Affairs, would be stepping down for "health reasons." Dr. Charnas's resignation will be effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration's scheduled review of Puma's breast cancer drug neratinib on May 24. Following this news, Puma stock dropped. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: http://www.bgandg.com/pbyi or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Puma you have until July 7, 2017 to request that … Continue reading →

Stocks Gallery Puma Biotechnology Inc (PBYI) Posts Earnings Results, Beats Expectations By $0.09 EPS The Cerbat Gem Puma Biotechnology logo Puma Biotechnology Inc (NYSE:PBYI) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.06) by ... Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Misled Shareholders According to a Recently Filed Class ActionBusiness Wire (press release) Why Analysts put forward these two stocks: Puma Biotechnology, Inc ...The USA Commerce Puma Biotechnology, Inc. (PBYI): From Top to BottomStockNewsJournal Stocks Gallery -Chaffey Breeze -BBNS all 67 news articles » Here is the original post: Puma Biotechnology Inc (PBYI) Posts Earnings Results, Beats Expectations By $0.09 EPS - The Cerbat Gem … Continue reading →